Generating novel crystal polymorphs of therapeutic compounds with uniform size distribution for improved solubility, hygroscopicity and manufacturability
Two pharmaceutical products for the treatment of neurological diseases developed by Neuractas Therapeutics require fine tuning to enhance their solubility, bioavailability and stability towards relative humidity. Extensive experimental research will be carried out to improve the polymorphic distribution of the products by high through-put crystallization to improve the solubility of one of the products. In addition, optimization of process variables such as the operating temperature, temperature profile, selection of appropriate tailor-made impurities will be conducted to ensure a uniform crystal size distribution with well-defined crystal habit to improve the physical stability, manufacturability and shelf life of the products. The outcome of this research will enable Neuractas Therapeutics, a Canadian pharmaceutical company, to develop compounds that benefit the patients, the economy and highly-skilled jobs in Canada.